Stock Track | GENSCRIPT BIO Soars 5.45% Intraday on Sector Optimism and Strong Associate Performance

Stock Track
05/13

GENSCRIPT BIO's stock surged 5.45% during intraday trading on Wednesday, reflecting significant investor interest in the biotechnology company.

The price movement appears to be driven by multiple positive factors. Eli Lilly's recent $7 billion acquisition of biotech firm Kelonia continues to boost sentiment across the entire cell therapy sector. Additionally, GenScript's associate company Legend Biotech reported robust first-quarter sales of approximately $597 million for its core product CARVYKTI, representing a substantial 61.8% year-over-year increase.

Analyst sentiment remains positive, with Morgan Stanley maintaining an "Overweight" rating and a HK$16.5 target price, while CICC maintains an "Outperform" rating with a HK$17.90 target price, both significantly above the current trading level.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10